Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

Now Viewing

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Dr. Chang delves into the operational considerations and complexities associated with implementing bispecific antibodies within a healthcare organization. The discussion emphasizes the need for a comprehensive approach, acknowledging the diverse disease states such as lymphoma and myeloma. She raises key questions about who will be responsible for and involved in operationalizing bispecifics, highlighting the importance of defining roles and establishing effective workflows.

The focus extends beyond traditional medical roles, involving pharmacy, physicians, nursing, and various stakeholders. Dr. Chang addresses the challenges faced by community practices compared to academic centers, emphasizing the importance of resource management. Stakeholders, including providers, nursing managers, pharmacy technicians, and the procurement department, are outlined with their specific roles in the process.

Financial considerations are highlighted, emphasizing the significant cost associated with these drugs. The financial staff's crucial role is underscored, involving tasks such as confirming insurance authorizations, navigating reimbursement processes, and collaborating with payers for accurate and timely reimbursement.

The pivotal role of clinical pharmacists is explored, particularly the regional clinical pharmacist as an operational champion. Their involvement in developing guidelines, standard procedures, and protocols for adverse events like CRS [cytokine release syndrome] and ICANS [immune effector cell-associated neurotoxicity syndrome] are highlighted. Additionally, the collaboration with manufacturers for education and training, ongoing challenges, and efforts for continuous improvement are discussed. The use of newsletters, podcasts, and training programs reflects a proactive approach to disseminating information and engaging a wider audience.

Overall, Dr. Chang provides a comprehensive overview of the multifaceted operational considerations and collaborative efforts required to successfully implement bispecific antibodies, showcasing a thoughtful and inclusive approach within the healthcare setting.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.